TITLE

Post-transplantation HTLV-1 myelopathy in three recipients from a single donor

AUTHOR(S)
Imirizaldu J J Zarranz; Esteban J C Gomez; Axpe I Rouco; Concha T Perez; Juanes F Velasco; Susaeta I Allue; Carranceja J M Corral
PUB. DATE
August 2003
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Aug2003, Vol. 74 Issue 8, p1080
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: This paper reports for the first time three cases of infection by HTLV-I via organ transplantation; all the organs coming from the same asymptomatic infected donor. The need is considered for the implementation of compulsory screenings for HTLV antibodies on organ donors and on blood banks. METHODS: The determination of antibodies for HTLV-I/II on samples of serum and cerebral spinal fluid from the patients and the donor was performed by enzyme immunoassay and western blot. Analysis of proviral DNA was performed by polymerase chain reaction. To detect changes in the sequence of amino acids, the tax gene was sequentiated, amplified, and compared with ATK prototype stocks. Spinal cord magnetic resonance imaging, cerebral spinal fluid, and somatosensory evoked potential studies were carried out in all patients. RESULTS: All three transplanted patients developed a myelopathy within a very short period of time. In all three patients and donor the virus belonged to the Cosmopolitan A subtype. The homology of HTLV-I sequences recovered from the patients and donor was 100% in all four cases. Proviral load was high in all three patients. The factors that certainly contributed to the infection in the first place, and the development of the disease later, were on the one hand the high proviral load and their immunosuppressed condition, and on the other the virus genotype, which proved to be an aggressive variant. However, the analysis of the histocompatibility antigen showed that two of the patients carried an haplotype that has been associated with a lower risk of developing this disease. CONCLUSIONS: It is argued that, although in Spain and other European countries there is not compulsory screening for HTLV antibodies because of the studies that show a low seroprevalence, in view of the cases here reported, and to avoid the serious consequences that such infection has on transplanted patients, compulsory screenings, both on organ donors and on blood banks, should be implemented.
ACCESSION #
10631508

 

Related Articles

  • Prevention of Cytomegalovirus Infection by Cytomegalovirus Immune Globulin After Marrow Transplantation. Meyers, Joel D.; Leszczynski, Jeanne; Zaia, John A.; Flournoy, Nancy; Newton, Barbara; Snydman, David R.; Wright, George G.; Levin, Myron J.; Thomas, E. Donnall // Annals of Internal Medicine;Apr83, Vol. 98 Issue 4, p442 

    Presents information on a study which described the prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Methods; Results; Discussion.

  • The Role of Leukocyte Depletion by in Vivo Use of Leukocyte Filter in Lung Preservation After Warm Ischemia. Ide, Hirofumi; Ino, Takashi; Hasegawa, Tsuguo; Matsumoto, Hiroshi // Angiology;Apr1990, Vol. 41 Issue 4, p318 

    The oxygen metabolites of leukocytes have been implicated as playing the central role in reperfusion injury of preserved lung for transplantation. Furthermore, it is still unknown how leukotrienes take part in this process. Twelve mongrel dogs were used, die vided into two groups. In group A,...

  • Evaluation of the highly sensitized transplant recipient. Stastny, Peter; Salvador, Ian-Michael; Lavingia, Bhavna // Pediatric Nephrology;Nov2011, Vol. 26 Issue 11, p1927 

    The immune response against alloantigens involves the production of antibodies and development of T-cell immunity. Recipients sensitized to HLA antigens may have antibodies to almost all donors and may not be able to find a suitable kidney transplant donor. Strategies available to enable these...

  • Beyond Antibody-Mediated Rejection: Hyperacute Lung Rejection as a Paradigm for Dysregulated Inflammation. Nguyen, Bao H.; Zwets, Egon; Schroeder, Carsten; Pierson III, Richard N.; Azimzadeh, Agnes M. // Current Drug Targets - Cardiovascular & Haematological Disorders;Jun2005, Vol. 5 Issue 3, p255 

    The use of animal organs for transplantation in humans is seen as a potential solution to the short supply of human donor organs available for clinical transplantation. However, to develop this therapeutic option as clinical reality will require surmounting formidable obstacles. The primary...

  • Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance. West, Lori J. // Current Drug Targets - Cardiovascular & Haematological Disorders;Jun2005, Vol. 5 Issue 3, p223 

    In order for ABO-incompatible organ transplantation to be performed successfully, the antibody response must be targeted. Aggressive strategies are usually required both to remove pre-existing antibodies directed at donor A/B antigens and to suppress further production of antibodies. If this can...

  • Modulating Alloimmune Responses with Plasmapheresis and IVIG. Warren, Daniel S.; Simpkins, Christopher E.; Cooper, Matthew; Montgomery, Robert A. // Current Drug Targets - Cardiovascular & Haematological Disorders;Jun2005, Vol. 5 Issue 3, p215 

    Antibody-mediated barriers to renal transplantation, including donor specific anti-HLA and anti-blood group antibodies, have become an increasingly important issue over the last forty years as the organ shortage has continued to expand. The inevitable result of the unmet demand for compatible...

  • The Role of HLA-Directed Antibodies in Cardiac Transplant Immunology. Tambur, Anat R. // Current Cardiology Reviews;2007, Vol. 3 Issue 3, p207 

    Over the last few years heart transplant physicians have encounted more allograft rejection episodes that are not responsive to conventional treatment. The role of B cells and alloantibodies in organ transplant outcome becomes more apparent. More centers recognize the role of humoral rejection...

  • One Lambda approved for C1qScreen assay.  // Medical Device Daily;11/14/2013, Vol. 17 Issue 221, p4 

    The article reports that in vitro diagnostic products company One Lambda was given CE mark approval for its C1qScreen assay in Europe in 2013.

  • © TRANSFER OF SENSITISED LYT 2+ CELLS TRIGGERS ACUTE REJECTION OF PANCREATIC ISLET ALLOGRAFTS. Prowse, Stephen J.; Warren, Hilary S.; Agostino, Michael; Lafferty, Kevin J. // Australian Journal of Experimental Biology & Medical Science;Apr1983, Vol. 61 Issue 2, p181 

    Examines the acute rejection of pancreatic islet allografts triggered by the transfer of sensitized LYT+ cells. Role of T cells in allograft rejection; Indefinite survival of pancreatic islet allografts in fully immunocompetent recipients; Treatment of the sensitized cells with either anti-Thy...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics